Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
clinical trials
3
×
eli lilly
fda
indiana blog main
indiana top stories
lasmiditan
3
×
life sciences
national blog main
raleigh-durham blog main
raleigh-durham top stories
amgen
boston top stories
boulder/denver blog main
boulder/denver top stories
colucid pharmaceuticals
detroit blog main
detroit top stories
galcanezumab
migraine
migraine research foundation
national
national top stories
new york blog main
new york top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
teva pharmaceutical
texas blog main
texas top stories
triptans
wisconsin blog main
wisconsin top stories
aimmune therapeutics
alder biopharmaceutical
What
approval
companies
decades
drug
fda
migraine
new
won
acute
addresses
arena’s
arguments
big
bio
bounty
causes
cig
class
comeback
commercialized
competitors
condition
corner
deals
delivered
drugs
eli
expressing
friday
giant
giving
ipo
lasmiditan
life
lilly
lilly’s
little
make
medication
meeting
Language
unset
Current search:
lasmiditan
×
" clinical trials "
×
@xconomy.com
4 years ago
FDA OKs Lilly’s Lasmiditan, First New Acute Migraine Drug in Decades
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Bio Roundup: Moderna’s IPO, Arena’s Comeback, E-Cig Survey & More